Abstract
Objective
We studied the alterations in the expression of estrogen receptor alpha (ER) in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDC).
Methods
The mastectomy specimens of 120 cases containing both DCIS and IDC were examined. The expression of ER proteins were examined by immunohistochemistry. The difference of the expression of ER proteins between DCIS and IDC were compared.
Results
There were 58.33% of the cases with DCIS expressing ER proteins, and 40.00% of the cases IDC expressing ER proteins. There was a significant decrease of ER expression in IDC compared to DCIS (χ2 = 4.034, P = 0.045).
Conclusion
These findings substantiate the notion that breast cancer progression is often associated with alterations in expressions of ER. The underlying mechanisms of these alterations need further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anim JT, John B, Abdulsathar S SA, et al. Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem, 2005, 107: 87–93.
Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast, 2008, 17: 523–527.
Hussein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int, 2008, 32: 698–707.
Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci, 2007, 37: 127–134.
Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol, 2008, 39: 386–392.
Meijnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer, 2008, 98: 137–142.
Ko SS, Na YS, Yoon CS, et al. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node-negative breast cancer: a tissue microarray study. Int J Surg Pathol, 2007, 15: 98–109.
Ayadi L, Khabir A, Amouri H, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol, 2008, 6: 112.
Al-Ahwal MS. HER-2 positivity and correlations with other histopathologic features in breast cancer patientse-hospital based study. J Pak Med Assoc, 2006, 56: 65–68.
Todorovic-Rakovic N. TGF-beta 1 could be a missing link in the interplay between ER and HER-2 in breast cancer. Med Hypotheses, 2005, 65: 546–551.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the National Science Foundation of China (No. 30772100).
Rights and permissions
About this article
Cite this article
Zhang, R., Liu, C., Jin, F. et al. Expression of ER protein from DCIS to IDC in ductal breast cancer. Chin. -Ger. J. Clin. Oncol. 8, 324–325 (2009). https://doi.org/10.1007/s10330-009-0064-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-009-0064-0